AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2004
Feb 17, 2004
35150_dirs_2004-02-17_bcfecb90-f87c-4d8e-a749-e2ee9c9b1bf2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: GENEMAX CORP (GMXX)
CIK: 0001094038
Period of Report: 2004-02-13
Reporting Person: MACKINNON NORMAN J R C A (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options | $1.00 | 2011-12-16 | Common Stock (25000) | Direct |
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17